Search research articles
Contact Us
Filters
Showing results (171-180 of 196) with videos related to
Page
of 20
Sort By:
International Journal of Cancer
|
September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2019
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Klaus-Peter Dieckmann, Arlo Radtke, Lajos Geczi, et al.
Minerva Urology and Nephrology
|
September 20, 2023
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy
Radosław Piszczek, Wojciech Krajewski, Jose D Subiela, et al.
BJU International
|
February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer
Pietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
European Urology Focus
|
May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment
Pietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
BJU International
|
February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer
Pietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Cancers
|
April 13, 2023
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
Francesco Del Giudice, Vincenzo Asero, Eugenio Bologna, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Urologic Oncology
|
April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin
Pietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 196) with videos related to
Sort By:
Page
of 20
International Journal of Cancer
|
September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2019
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Klaus-Peter Dieckmann, Arlo Radtke, Lajos Geczi, et al.
Minerva Urology and Nephrology
|
September 20, 2023
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy
Radosław Piszczek, Wojciech Krajewski, Jose D Subiela, et al.
BJU International
|
February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer
Pietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
European Urology Focus
|
May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment
Pietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
BJU International
|
February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer
Pietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Cancers
|
April 13, 2023
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
Francesco Del Giudice, Vincenzo Asero, Eugenio Bologna, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Urologic Oncology
|
April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin
Pietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Page
of 20